---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-174458"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:10:36.962197+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Soleno Q2 2025: $32.7M product revenue from VYKAT XR launch; net loss $4.7M

## Summary
- Product revenue, net $32.7M for Q2 2025, first quarter with VYKAT XR sales (launched April 14).
- Net loss $(4.7)M or ($0.09) per share vs. $(21.9)M ($0.57) in Q2 2024.
- Cash, equivalents and marketable securities $293.8M at June 30; subsequent $230M equity offering in July.
- Launch metrics: 646 patient start forms, 295 unique prescribers, >100M lives covered by end of Q2.
- MAA for DCCR submitted to EMA; contingent consideration liability for sales milestones estimated at $18.9M.

## SEC filing metadata
- accession: 0001193125-25-174458
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312525174458/0001193125-25-174458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312525174458/d88313d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-174458
- JSON: https://secwatch.observer/filing/0001193125-25-174458.json
- Plain text: https://secwatch.observer/filing/0001193125-25-174458.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.